From 2481673bb6ea33e342f6cfb4be5c92a5485a8bca Mon Sep 17 00:00:00 2001 From: Borja Robert Date: Tue, 20 Feb 2024 12:41:07 +0100 Subject: [PATCH] Auto saved by Logseq --- pages/STOP2030___Web___Update 2024___02.md | 5 ++++- 1 file changed, 4 insertions(+), 1 deletion(-) diff --git a/pages/STOP2030___Web___Update 2024___02.md b/pages/STOP2030___Web___Update 2024___02.md index e223a864..4a5a2b35 100644 --- a/pages/STOP2030___Web___Update 2024___02.md +++ b/pages/STOP2030___Web___Update 2024___02.md @@ -97,7 +97,10 @@ - Un safety and effectiveness study - Primary objective: evaluate and compare safety of the [[FDC]] against [[albendazole]] alone via [[MDA]] in two study areas in [[Kenya]] and [[Ghana]] - Secondary objectives: - - Evaluate the effectiveness of one round of MDA with FDC vs albendazole against STH by microscopy + - Evaluate the effectiveness of one round of [[MDA]] with [[FDC]] vs [[albendazole]] against [[STH]] by microscopy + - Evaluate the effectiveness of one round of [[MDA]] with [[FDC]] vs [[albendazole]] against [[Strongyloides stercolaris]] by serology + - Primary goal: Safety (incidence of SAEs) + - Secondary goals: Effectiveness at - Nuestros objetivos: - Overall goal: Support the achievement of the [[WHO]] 2030 NTD Roadmap for [[STH]] and beyond - Project purpose: Advance and accelerate an innovative pharmacological tool to support the elimination goals against [[STH]] species, especially those poorly responsive to current treatment regimens \ No newline at end of file